Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4GT
|
|||
| Former ID |
DIB007553
|
|||
| Drug Name |
131I-radretumab
|
|||
| Synonyms |
L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
| Company |
ETH Zurich
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01242943) Radioimmunotherapy With 131I-L19SIP in Patients With Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.